References
Key articles
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia [internet publication].Full text
Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-84.Full text Abstract
Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(Suppl 4):iv41-51.Full text Abstract
Smith G, Apperley J, Milojkovic D, et al. A British Society for Haematology guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020 Oct;191(2):171-93.Full text Abstract
Reference articles
1. Sawyers C. Chronic myeloid leukemia. N Engl J Med. 1999 Apr 29;340(17):1330-40. Abstract
2. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009 Jun;23(6):1054-61. Abstract
3. Druker BJ, Guilhot F, O'Brien SG, et al; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 Dec 7;355(23):2408-17.Full text Abstract
4. Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016 Jan;30(1):48-56. Abstract
5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia [internet publication].Full text
6. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-84.Full text Abstract
7. Zhang XS, Gale RP, Huang XJ, et al. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors? Leukemia. 2022 Feb;36(2):482-91.Full text Abstract
8. Pfirrmann M, Clark RE, Prejzner W, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020 Aug;34(8):2138-49.Full text Abstract
9. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984 Apr;63(4):789-99.Full text Abstract
10. Hasford J, Pfirrmann M, Hehlmann R, et al; Writing Committee for the Collaborative CML Prognostic Factors Project Group. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998 Jun 3;90(11):850-8.Full text Abstract
11. Goldman J. ABC of clinical haematology: chronic myeloid leukaemia. BMJ. 1997 Mar 1;314(7081):657-60. [Erratum in: BMJ 1997 Mar 15;314(7083):812.]Full text Abstract
12. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: leukemia - chronic myeloid leukemia (CML). 2024 [internet publication].Full text
13. American Cancer Society. Key statistics for chronic myeloid leukemia. 2024 [internet publication].Full text
14. Haematological Malignancy Research Network. Factsheets: chronic myeloid leukaemia. 2022 [internet publication].Full text
15. Ali Hailan YM, Al-Dubai HN, Yassin MA. Chronic myeloid leukemia following exposure to radioactive iodine (I131): a systematic review. Oncology. 2023;101(6):362-8.Full text Abstract
16. Tsushima H, Iwanaga M, Miyazaki Y. Late effect of atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes. Int J Hematol. 2012 Mar;95(3):232-8. Abstract
17. Schubauer-Berigan MK, Daniels RD, Fleming DA, et al. Risk of chronic myeloid and acute leukemia mortality after exposure to ionizing radiation among workers at four U.S. nuclear weapons facilities and a nuclear naval shipyard. Radiat Res. 2007 Feb;167(2):222-32. Abstract
18. Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med. 1999 Jul 15;341(3):164-72. Abstract
19. American Cancer Society. Risk factors for chronic myeloid leukemia. Feb 2024 [internet publication].Full text
20. Jones D, Kamel-Reid S, Bahler D, et al. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. J Mol Diagn. 2009 Jan;11(1):4-11.Full text Abstract
21. Adnan-Awad S, Kim D, Hohtari H, et al. Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. Leukemia. 2021 Jul;35(7):1964-75.Full text Abstract
22. Adnan-Awad S, Hohtari H, Javarappa KK, et al. BCR-ABL1 p190 in CML: a minor breakpoint with a major impact. Blood. 2019 Nov;134(1 suppl):190.Full text
23. Au WY, Caguioa PB, Chuah C, et al. Chronic myeloid leukemia in Asia. Int J Hematol. 2009 Jan;89(1):14-23. Abstract
24. Kuan JW, Melaine Michael S. The epidemiology of chronic myeloid leukaemia in southern Sarawak, Borneo Island. Med J Malaysia. 2018 Apr;73(2):78-85.Full text Abstract
25. Jootar S. CML treatment in Asia-Pacific region. Hematology. 2012 Apr;17 Suppl 1:S72-4.Full text Abstract
26. Mendizabal AM, Garcia-Gonzalez P, Levine PH. Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries. Cancer Epidemiol. 2013 Jun;37(3):247-54. Abstract
27. Ural AU, Beyzadeoglu M, Avcu F, et al. Chronic myeloid leukemia following radiotherapy for carcinoma of the cervix: report of a case and brief review of the literature. Am J Hematol. 2007 May;82(5):415-6.Full text Abstract
28. Miyoshi I, Mori M, Yamasaki I, et al. Is there an entity of radiation-induced chronic myeloid leukemia? Report of a case and brief review of the literature. J Clin Exp Hematop. 2020;60(1):24-5.Full text Abstract
29. Leuraud K, Richardson DB, Cardis E, et al. Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study. Lancet Haematol. 2015 Jul;2(7):e276-81.Full text Abstract
30. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024 Nov;99(11):2191-212.Full text Abstract
31. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukemia seen at a referral center over a 16-year period. Br J Haematol. 1997 Jan;96(1):111-6. Abstract
32. Liu Z, Shi Y, Yan Z, et al. Impact of anemia on the outcomes of chronic phase chronic myeloid leukemia in TKI era. Hematology. 2020 Dec;25(1):181-5.Full text Abstract
33. Sevastos N, Theodossiades G, Efstathiou S, et al. Pseudohyperkalemia in serum: the phenomenon and its clinical magnitude. J Lab Clin Med. 2006 Mar;147(3):139-44. Abstract
34. Cross NCP, Ernst T, Branford S, et al. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 2023 Nov;37(11):2150-67.Full text Abstract
35. Müller MC, Cross NC, Erben P, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia. 2009 Nov;23(11):1957-63. Abstract
36. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405.Full text Abstract
37. Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(Suppl 4):iv41-51.Full text Abstract
38. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukemias. Proposals by the French-American-British Cooperative Leukemia Group. Br J Haematol. 1994 Aug;87(4):746-54. Abstract
39. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007 Aug 15;110(4):1092-7.Full text Abstract
40. Kantarjian HM, Deisseroth A, Kurzrock R, et al. Chronic myelogenous leukemia: a concise update. Blood. 1993 Aug 1;82(3):691-703.Full text Abstract
41. Cree IA. The WHO classification of haematolymphoid tumours. Leukemia. 2022 Jul;36(7):1701-2.Full text Abstract
42. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022 Jul;36(7):1703-19.Full text Abstract
43. Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200-28.Full text Abstract
44. Alberta Health Services. Chronic myeloid leukemia. Oct 2023 [internet publication].Full text
45. Smith G, Apperley J, Milojkovic D, et al. A British Society for Haematology guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020 Oct;191(2):171-93.Full text Abstract
46. Bower H, Björkholm M, Dickman PW, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016 Aug 20;34(24):2851-7.Full text Abstract
47. Sasaki K, Strom SS, O'Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015 May;2(5):e186-93.Full text Abstract
48. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003 May 15;101(10):3794-800.Full text Abstract
49. Cortes J, Quintás-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer. 2011 Mar 15;117(6):1113-22.Full text Abstract
50. Radich JP, Hochhaus A, Masszi T, et al. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia. 2021 May;35(5):1344-55.Full text Abstract
51. O'Brien SG, Guilhot F, Larson RA, et al; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003 Mar 13;348(11):994-1004.Full text Abstract
52. Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017 Mar 9;376(10):917-27.Full text Abstract
53. Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015 May;29(5):1123-32. Abstract
54. Hehlmann R, Lauseker M, Saußele S, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017 Nov;31(11):2398-406.Full text Abstract
55. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med.2006 Jun 15;354(24):2542-51.Full text Abstract
56. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008 Jul 1;26(19):3204-12.Full text Abstract
57. Talpaz M, Shah N, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15;354(24):2531-41.Full text Abstract
58. Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive CML patients with resistance or intolerance to imatinib. Blood. 2011 Oct 27;118(17):4567-76.Full text Abstract
59. Hochhaus A, Wang J, Kim DW, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024 Sep 12;391(10):885-98. Abstract
60. Yeung DT, Shanmuganathan N, Reynolds J, et al. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study. Blood. 2024 Nov 7;144(19):1993-2001. Abstract
61. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun 17;362(24):2251-9.Full text Abstract
62. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012 Oct;26(10):2197-203. Abstract
63. Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly fiagnosed vhronic myeloid leukemia: results From the randomized BFORE trial. J Clin Oncol. 2018 Jan 20;36(3):231-7.Full text Abstract
64. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016 Jul 10;34(20):2333-40.Full text Abstract
65. Brümmendorf TH, Cortes JE, Milojkovic D, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022 Jul;36(7):1825-33.Full text Abstract
66. Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021 Feb;35(2):440-53.Full text Abstract
67. Réa D, Mauro MJ, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021 Nov 25;138(21):2031-41.Full text Abstract
68. Hochhaus A, Réa D, Boquimpani C, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023 Mar;37(3):617-26.Full text Abstract
69. Lauseker M, Hehlmann R, Hochhaus A, et al. Survival with chronic myeloid leukaemia after failing milestones. Leukemia. 2023 Nov;37(11):2231-6.Full text Abstract
70. Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood. 2009 Dec 24;114(27):5426-35.Full text Abstract
71. Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019 Dec 12;381(24):2315-26.Full text Abstract
72. Saussele S, Haverkamp W, Lang F, et al. Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute leukemia: recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management. Acta Haematol. 2020;143(3):217-31.Full text Abstract
73. Müller MC, Cervantes F, Hjorth-Hansen H, et al. Ponatinib in chronic myeloid leukemia (CML): consensus on patient treatment and management from a European expert panel. Crit Rev Oncol Hematol. 2017 Dec;120:52-9.Full text Abstract
74. Cortes JE, Kim DW, Pinilla-Ibarz J, et al; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov 7;369(19):1783-96.Full text Abstract
75. Medicines and Healthcare products Regulatory Agency. Ponatinib (Iclusig): reports of posterior reversible encephalopathy syndrome. Oct 2018 [internet publication].Full text
76. Cortes J, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021 Nov 25;138(21):2042-50.Full text Abstract
77. Pulte ED, Chen H, Price LSL, et al. FDA approval summary: revised indication and dosing regimen for ponatinib based on the results of the OPTIC trial. Oncologist. 2022 Mar 4;27(2):149-57.Full text Abstract
78. Saifullah HH, Lucas CM. Treatment-free remission in chronic myeloid leukemia: can we identify prognostic factors? Cancers (Basel). 2021 Aug 19;13(16):4175.Full text Abstract
79. Ross DM, Hughes TP. Treatment-free remission in patients with chronic myeloid leukaemia. Nat Rev Clin Oncol. 2020 Aug;17(8):493-503. Abstract
80. Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018 Jun;19(6):747-57. Abstract
81. Niederwieser C, Kröger N. Transplantation in CML in the TKI era: who, when, and how? Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):114-22.Full text Abstract
82. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: hematopoietic cell transplantation [internet publication].Full text
83. Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood. 2007 Apr 1;109(7):2791-3.Full text Abstract
84. Olavarria E, Siddique S, Griffiths MJ, et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood. 2007 Dec 15;110(13):4614-7.Full text Abstract
85. DeFilipp Z, Langston AA, Chen Z, et al. Does post-transplant maintenance therapy with tyrosine kinase inhibitors improve outcomes of patients with high-risk Philadelphia chromosome-cositive leukemia? Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):466-471.e1. Abstract
86. Lübking A, Dreimane A, Sandin F, et al. Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. Bone Marrow Transplant. 2019 Nov;54(11):1764-74. Abstract
87. Shimada H, Tanizawa A, Kondo T, et al. Prognostic factors for outcomes of allogeneic HSCT for children and adolescents/young adults with CML in the TKI era. Transplant Cell Ther. 2022 Jul;28(7):376-89.Full text Abstract
88. Niederwieser C, Morozova E, Zubarovskaya L, et al. Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML. Bone Marrow Transplant. 2021 Nov;56(11):2834-41.Full text Abstract
89. Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009 Jun 18;113(25):6322-9.Full text Abstract
90. Murai K, Ureshino H, Kumagai T, et al. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2021 Dec;8(12):e902-11. Abstract
91. Itamura H, Kubota Y, Shindo T, et al. Elderly patients with chronic myeloid leukemia benefit from a dasatinib dose as low as 20 mg. Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):370-4. Abstract
92. La Rosée P, Martiat P, Leitner A, et al. Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol. 2013 Oct;92(10):1345-50. Abstract
93. ClinicalTrials.gov. TKI and interferon alpha evaluation initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study (TIGER). NCT01657604. May 2023 [internet publication].Full text
94. Hochhaus A, Burchert A, Saußele S, et al. S157: nilotinib vs. nilotinib + peg-interferon αlpha induction and nilotinib or peg-interferon αlpha maintenance therapy for newly diagnosed chronic myeloid leukemia patients - the TIGER trial. Hemasphere. 2023 Aug;7(Suppl):e4695659.Full text
95. Jiang Q, Li Z, Qin Y, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2022 Aug 18;15(1):113.Full text Abstract
96. ClinicalTrials.gov. Study of olverembatinib (HQP1351) in patients with CP-CML (POLARIS-2). Aug 2024 [internet publication].Full text
97. ClinicalTrials.gov. Treatment with olverembatinib in CML-CP patients who failed to at least two previously administered second-generation TKIs. Jul 2022 [internet publication].Full text
98. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER explorer [internet publication].Full text
99. Kantarjian H, Sawyers C, Hochhaus A, et al; International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002 Feb 28;346(9):645-52. [Erratum in: N Engl J Med. 2002 Jun 13;346(24):1923.]Full text Abstract
100. Fachi MM, Tonin FS, Leonart LP, et al. Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: a network meta-analysis. Br J Clin Pharmacol. 2019 Oct;85(10):2280-91.Full text Abstract
101. Cortes JE, Jimenez CA, Mauro MJ, et al. Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management. Clin Lymphoma Myeloma Leuk. 2017 Feb;17(2):78-82.Full text Abstract
102. Brixey AG, Light RW. Pleural effusions due to dasatinib. Curr Opin Pulm Med. 2010 Jul;16(4):351-6. Abstract
103. Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015 Dec 10;33(35):4210-8. Abstract
104. Jain P, Kantarjian H, Boddu PC, et al. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 Mar 26;3(6):851-61.Full text Abstract
105. Aldapt MB, Al-Mashdali AF, Obeidat K, et al. Viral infections and incidence of reactivations in chronic myeloid leukemia patients. Oncology. 2024;102(4):380-8.Full text Abstract
106. Centers for Disease Control and Prevention. Underlying conditions and the higher risk for severe COVID-19. Jul 2024 [internet publication].Full text
107. American Society of Hematology. Treatment of COVID-19 in immunocompromised patients with hematologic conditions. Sep 2022 [internet publication].Full text
108. Teh JSK, Coussement J, Neoh ZCF, et al. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Adv. 2022 Apr 12;6(7):2014-34.Full text Abstract
109. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prevention and treatment of cancer-related infections [internet publication].Full text
Use of this content is subject to our disclaimer